Navigation Links
The Leukemia & Lymphoma Society Awards Major Grant to Stanford Researcher
Date:9/30/2008

LLS Specialized Center of Research Program Hits $178 Million Mark

WHITE PLAINS, N.Y., Sept. 30 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded a new Marshall A. Lichtman Specialized Center of Research (SCOR) grant to Beverly Mitchell, M.D., George E. Becker Professor of Medicine at Stanford University.

Dr. Mitchell and her team will receive $1.25 million a year for five years, for a total of $6.25 million. The SCOR program is LLS's largest research grant, with total funding of $178.25 million since its inception in 2000. The title of her SCOR is: Molecular and Cellular Characterization of Myelodysplastic Syndromes.

The SCOR program brings together teams of researchers representing different disciplines in collaborative efforts to discover new approaches to treat patients with leukemia, lymphoma and myeloma. Awards go to groups that best demonstrate outstanding scientific promise facilitated by the synergy that will occur from their combined efforts.

Dr. Mitchell's team is studying stem cells in myelodysplastic syndromes (MDS), a collection of related disorders in which damaged bone marrow cells can't mature into functional blood cells. The disorders frequently progress to acute myelogenous leukemia (AML). Her team has recently identified new molecular markers than can help identify the MDS stem cells that have progressed to AML, and are working to develop therapies to target these abnormal MDS stem cells. A clinical trial of an investigational drug that targets one of the enzymes involved in the development of MDS will be initiated.

"Dr. Mitchell and her team of investigators are undertaking cutting-edge research to reach a better understanding of the root causes of MDS," said Louis DeGennaro, Ph.D., LLS's chief scientific officer. "Their work will likely lead to new therapies that target these diseases. This research team is an impressive addition to the outstanding scientists already in the SCOR program."

SCOR is one of three integrated research grant programs established by LLS. These also include the Career Development Program, which provides stipends to investigators of exceptional promise in the early stages of their careers; and the Translational Research Program, which encourages and supports outstanding research with strong promise of translating emerging biomedical knowledge into new treatments. In addition, the Therapy Acceleration Program is designed to help move potential therapies more quickly through the development pipeline.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society, headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, LLS has invested more than $600 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, LLS made 6.3 million contacts with patients, caregivers and healthcare professionals.

For more information about blood cancer, visit http://www.LLS.org or call LLS's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.
Andrea Greif

914-821-8958

andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New leukemia signal could point way to better treatment, Stanford researchers find
2. The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years
3. Stater Bros. Raises $200,000 for the Leukemia & Lymphoma Society
4. Methadone Kills Resistant Leukemia Cells
5. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
6. Leukemia drug could save lives of stroke patients
7. Math could help cure leukemia
8. Gene mutation improves leukemia drugs effect
9. Microenvironment a main driver of aggressive multi-lineage leukemia disease type
10. Clinical study shows biological and clinical activity in relapsed leukemia patients
11. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... NY (PRWEB) , ... December 07, 2016 , ... A. ... business owners and families throughout the Five Boroughs, is launching a charity drive to ... works to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu ... fully redesigned website, which launched October 17, 2016, features comprehensive information regarding a ... easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments for ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... condemning "scam operations" carried out by unethical locksmith companies and is urging Search ... a halt. According to Texas Premier Locksmith, these fraudulent locksmith services take advantage ...
(Date:12/7/2016)... ... 07, 2016 , ... "ProBrand Flip allows FCPX editors to create unique logo ... CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip book reveal animations. ... select from a variety of flip book animations. In Addition, users can modify each ...
(Date:12/7/2016)... ... 2016 , ... Maureen McLaughlin, LA.c., a certified acupuncturist, is ... Connecticut (RMACT). McLaughlin brings nearly 20 years of experience with fertility patients to ... their family building goals. Acupuncture helps fertility patients by supporting the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... 2016   Arena Pharmaceuticals, Inc. (NASDAQ: ... enrollment in the ralinepag phase 2 trial.  Ralinepag is ... pathway for the treatment of pulmonary arterial hypertension (PAH). ... "This marks an important step in the ... focus on our pipeline," said Amit Munshi , ...
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... Dec. 7,2016  Based on its recent ... Frost & Sullivan recognizes Nemaura Pharma Limited ... Award for Enabling Technology Leadership. Nemaura Pharma,s ... in traditional drug delivery technologies, especially in ... drug delivery technologies, Memspatch and Micropatch respectively, ...
Breaking Medicine Technology: